A first step in the development of a new treatment for a disease is the identification of a biological target. In Academia planned publications demand a fast decision on whether and what should be patented at such an early stage. However, what can be patented around a biological target? What data is necessary to do so? What makes sense from an economical point of view? And what makes sense from the view-point of an Academic Institute? The planned panel discussion will address these questions.
For more information about the program, please see poster on the right hand side.